Eli Lilly's Immunology division generated $2.6 billion in revenues in H1 2026, up 9% year-over-year, representing 6.1% of total revenues. Led by Taltz, the portfolio is expanding through newer products like Ebglyss and Omvoh, plus strategic acquisitions of DICE, Morphic, and Merida to strengthen its pipeline across IBD, autoimmune diseases, and allergies. However, the company faces intense competition from established players and newer therapies.

Vanguard's VHT and State Street's XPH offer different approaches to healthcare investing. VHT provides broad sector exposure with lower costs (0.09% expense ratio) and higher dividend yield (1.5%), making it ideal for long-term investors. XPH focuses on pharmaceuticals with higher volatility but stronger 1-year returns (57.2% vs 29.3%), appealing to growth-oriented investors willing to accept greater risk.

Zacks equity research analysts featured four stocks in their daily blog: Eli Lilly benefiting from strong GLP-1 drug demand with pipeline progress; Palo Alto Networks outperforming the security industry through platformization and AI-driven threat defenses; Texas Instruments gaining from broadening demand across industrial, data center and automotive markets; and Stratus Properties executing a board-approved liquidation plan with near-term asset disposition catalysts.

The global monoclonal antibodies market is projected to grow from USD 280.15 billion in 2025 to USD 791.28 billion by 2035, driven by increasing demand for targeted therapies in oncology, autoimmune disorders, and chronic diseases. North America leads with 41% market share, while Asia-Pacific shows the fastest growth at 12.32% CAGR. Key innovations include bispecific antibodies and antibody-drug conjugates, with humanized antibodies emerging as the fastest-growing segment.

The article compares two healthcare-focused ETFs from iShares: IHE (Pharmaceuticals ETF) with 55 holdings and IYH (Healthcare ETF) with 100 holdings. While IHE delivered stronger 1-year returns of 50% versus IYH's 27.4%, the article recommends IYH as the better choice due to superior 3- and 5-year performance, greater diversification, and larger asset base of $3.9B. Both funds have identical 0.37% expense ratios.

Novo Nordisk's stock has declined 66% from its 2024 high and now trades at attractive valuations compared to historical averages. While the company lost its GLP-1 weight-loss drug market lead to Eli Lilly, it is attempting a comeback through a new GLP-1 pill and a volume-driven pricing strategy. Despite significant uncertainty around its competitive position and business transition, the stock's low valuation and 3.7% dividend yield may appeal to value and dividend investors.

The article examines the reliability of Wall Street analyst recommendations versus the Zacks Rank system. While Eli Lilly has a strong average brokerage recommendation (ABR) of 1.45 (Buy-equivalent), the article cautions that brokerage analysts often exhibit positive bias due to vested interests. In contrast, the Zacks Rank, which is based on earnings estimate revisions, has demonstrated superior predictive power for near-term stock price movements. Lilly's unchanged consensus estimate resulted in a Zacks Rank #3 (Hold), suggesting caution despite the bullish ABR.

Novo Nordisk announced positive phase III STEP Young study results showing semaglutide reduced BMI in children aged 6-12 with obesity, with 40.4% no longer classified as obese after 68 weeks. However, the company faces mounting competitive pressure from Eli Lilly's superior weight-loss drugs and emerging biotech competitors in the GLP-1 obesity treatment market.

Eli Lilly's neuroscience business, currently representing only 2% of revenues, is experiencing strong 32% growth with key products Kisunla and Emgality. The company is aggressively expanding its neuroscience pipeline through acquisitions including AtaiBeckley for treatment-resistant depression therapies, positioning neuroscience as a potential long-term growth driver to diversify beyond its dominant cardiometabolic business.

Cloverleaf Bio, a Yale spinout RNA therapeutics company, closed a $33 million oversubscribed seed round led by 4BIO Capital with strategic participation from AbbVie Ventures, Eli Lilly, and Boehringer Ingelheim Venture Fund. The funding will advance the company's engineered tRNA platform for cancer treatment, with lead programs targeting hepatocellular carcinoma and colorectal cancer. Preclinical data shows the platform demonstrates superior potency and selectivity for cancer cells over healthy tissue.

The radioligand therapy market is projected to grow at an 18.2% CAGR through 2035, driven by increased prostate cancer and neuroendocrine tumor cases, FDA approvals for PSMA-targeted therapies like Pluvicto, and expanded isotope production capacity. North America dominates with 80.5% market share, while Asia-Pacific is the fastest-growing region at 21.5% CAGR.

Eli Lilly's GLP-1 weight-loss drugs (Mounjaro, Zepbound) currently drive nearly two-thirds of revenue, but face competition and patent expiration risks. The company is strategically acquiring smaller biotech firms across autoimmune, mental health, sleep disorders, and infectious disease spaces to diversify its pipeline and prepare for when GLP-1 drugs are no longer its primary revenue driver.